May 21, 2026
Sebastián Malleza
After completing this activity, participants should be able to: 1. Describe the pharmacological mechanism of dextromethorphan/bupropion as an oral NMDA receptor antagonist and σ-1 agonist paired with a CYP2D6-inhibiting NDRI, explain how bupropion's CYP2D6 inhibition enhances dextromethorphan's bioavailability and extends its half-life ~3-fold, and identify its two FDA-approved indications —...
May 21, 2026
Sebastián Malleza
Nach Abschluss dieser Fortbildung sollten die Teilnehmer in der Lage sein: Den pharmakologischen Wirkmechanismus von Dextromethorphan/Bupropion als oraler NMDA-Rezeptor-Antagonist und σ-1-Agonist in Kombination mit einem CYP2D6-hemmenden NDRI zu beschreiben, zu erläutern, wie die CYP2D6-Hemmung durch Bupropion die Bioverfügbarkeit von Dextromethorphan erhöht und dessen Halbwertszeit um das ca....
May 21, 2026
Sebastián Malleza
À l'issue de cette activité, les participants devraient être en mesure de : Décrire le mécanisme pharmacologique du dextrométhorphane/bupropion en tant qu'antagoniste oral des récepteurs NMDA et agoniste σ-1 associé à un NDRI inhibiteur du CYP2D6, expliquer comment l'inhibition du CYP2D6 par le bupropion augmente la biodisponibilité du dextrométhorphane et prolonge sa demi-vie d'environ 3 fois,...
August 8, 2025
Sebastián Malleza
After completing this activity, participants should be able to: Identify the unique pharmacological mechanism of dextromethorphan/bupropion as an oral NMDA receptor antagonist combination and describe how bupropion's CYP2D6 inhibition enhances dextromethorphan's bioavailability to produce rapid antidepressant effects within the first week of treatment. Recognize absolute contraindications for...
July 11, 2025
Sebastián Malleza
Após concluir esta atividade, os participantes deverão ser capazes de: Analisar os mecanismos farmacodinâmicos da cetamina, incluindo sua ação primária como antagonista do receptor NMDA e efeitos secundários sobre os receptores AMPA, sistemas opioides e vias de neuroplasticidade, a fim de otimizar a seleção do tratamento para pacientes com depressão resistente ao tratamento. Avaliar cenários...
July 11, 2025
Sebastián Malleza
Na het voltooien van deze activiteit moeten deelnemers in staat zijn om: De farmacodynamische mechanismen van ketamine te analyseren, inclusief de primaire werking als NMDA-receptorantagonist en secundaire effecten op AMPA-receptoren, opioïde systemen en neuroplasticiteitspathways, om de behandelkeuze voor patiënten met therapieresistente depressie te optimaliseren. Klinische scenario's te...
July 11, 2025
Sebastián Malleza
After completing this activity, participants should be able to: Analyze the pharmacodynamic mechanisms of ketamine, including its primary action as an NMDA receptor antagonist and secondary effects on AMPA receptors, opioid systems, and neuroplasticity pathways, to optimize treatment selection for patients with treatment-resistant depression. Evaluate clinical scenarios to determine when...
June 13, 2025
Sebastián Malleza
After completing this activity, participants should be able to: Describe the mechanism of action, pharmacokinetics, and pharmacodynamics of esketamine in the treatment of depression. Evaluate the efficacy, dosing strategies, and clinical considerations for using esketamine in treatment-resistant depression and major depression with suicidal ideation. Identify and manage common and serious...
June 13, 2025
Sebastián Malleza
Na het voltooien van deze activiteit moeten deelnemers in staat zijn om: Het werkingsmechanisme, de farmacokinetiek en de farmacodynamiek van esketamine bij de behandeling van depressie te beschrijven. De werkzaamheid, doseringstrategieën en klinische overwegingen voor het gebruik van esketamine bij therapieresistente depressie en ernstige depressie met suïcidale ideatie te evalueren....